

Replacement claims 1, 13 and 14

72 sub 1
1. (Once Amended) A method for preventing or treating a disease or condition caused, or contributed to, by lipolysis or elevated FFA levels in a subject, comprising administering to the subject a pharmaceutically effective amount of an inhibitor of a MAPK pathway to reduce lipolysis, to thereby prevent or treat the disease or condition in the subject.

A2
13. (Once Amended) A method for treating a subject having insulin resistance, comprising administering to the subject a pharmaceutically effective amount of an inhibitor of ERK1/2 and/or JNK pathway in an amount sufficient to decrease lipolysis.

14. (Once Amended) A method for treating a subject having NIDDM, comprising administering to the subject a pharmaceutically effective amount of an inhibitor of the ERK1/2 and/or JNK pathway in an amount sufficient to decrease lipolysis.